Get the Stockscreener App
2.07
3.94%
-0.085
After Hours:
2.13
0.06
+2.90%
Cabaletta Bio Inc stock is traded at $2.07, with a volume of 3.09M.
It is down -3.94% in the last 24 hours and down -35.71% over the past month.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
See More
Previous Close:
$2.155
Open:
$2.17
24h Volume:
3.09M
Relative Volume:
0.61
Market Cap:
$350.96M
Revenue:
-
Net Income/Loss:
$-175.43M
P/E Ratio:
-1.0488
EPS:
-1.9736
Net Cash Flow:
$-143.28M
1W Performance:
-18.82%
1M Performance:
-35.71%
6M Performance:
-25.54%
1Y Performance:
-10.39%
1-Day Range:
$2.05
$2.17
1-Week Range:
$2.05
$2.65
52-Week Range:
$2.00
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.07 | 350.96M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Resumed | Jefferies | Buy |
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Electra's IPO Break, Three CAR-T Deaths, and a Tariff Deadline Nobody Understands - finance.biggo.com
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Inc (NASDAQ: CABA) Share Price, CABA Stock News, CABA Share Price & Updates - kalkine.com.au
Cabaletta Bio Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest ReliefSlow Growth Warning - careplusvn.com
Cabaletta Bio (NASDAQ: CABA) Raises $128.2M from Warrant Exercises by September 12, 2026 - Kalkine Media
Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration By Investing.com - Investing.com South Africa
Form 8K Cabaletta Bio Inc For: 14 September By Investing.com - Investing.com Australia
Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration - Investing.com
Cabaletta Bio warrant exercises bring $128.2M gross proceeds after June 2025 offering - TradingView
$2.50 share warrants bring new cash to Cabaletta Bio (CABA) - Stock Titan
Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale By Investing.com - Investing.com Canada
Cactus Cuts Q3 Pressure Control Outlook on Expected Double-Digit Revenue Decline - Minichart
Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - Moomoo
Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors - MyChesCo
CABA Stock Price and Chart — NASDAQ:CABA - TradingView
Cabaletta Bio Inc. (CABA) Key Financial Ratios – Valuation, Profitability & More - Value Research
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo
CABA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $16 - GuruFocus
Cabaletta Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio Inc. (CABA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta (CABA) Earnings Reading: EPS Lands Above Forecast in the Current Update; Post-Report: Shares Finish 0.96% Down in the Available RecordProfit Growth Outlook - vinanet.vn
Blue Owl Capital Holdings LP Acquires New Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner - Endpoints News
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Trading 10.3% HigherShould You Buy? - MarketBeat
Norges Bank Initiates New Position in Cabaletta Bio (CABA) With 8.7 Million Share Purchase - GuruFocus
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio (CABA) Rallies 5% as Biotech Sentiment ImprovesForce Index - vinanet.vn
HC Wainwright Raises Earnings Estimates for Cabaletta Bio - MarketBeat
Cabaletta Bio (CABA) Reports Promising Phase 1/2 Data Amid Unpro - GuruFocus
668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA) - The Globe and Mail
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00 - GuruFocus
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Cabaletta Bio Releases Q2 2026 Financial Results - AlphaStreet
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Australia
Why is Cabaletta Bio stock sliding today? - Investing.com
Cabaletta Bio Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Cabaletta Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio (CABA) Q2 Earnings Beat Expectations; Market Focuses on Growth Potential Despite Losses - GuruFocus
Form 8K Cabaletta Bio Inc For: 13 August By Investing.com - Investing.com Nigeria
Cabaletta Bio Q2 net loss widens as R&D costs rise - TradingView
Cabaletta Bio, Inc. 2Q 2026: Net loss $(51.0)M, EPS $(0.34) — 10-Q Summary - TradingView
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):